airis Pharma
Hyderabad, India· Est.
Indian generic drug developer delivering high‑complexity oral and injectable formulations for US and global markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Indian generic drug developer delivering high‑complexity oral and injectable formulations for US and global markets.
Technology Platform
Continuous‑quality cGMP manufacturing combined with integrated analytical services (raw material, packaging, stability) to enable rapid, scalable production of complex oral solid and injectable generics.
Opportunities
Expanding the FDA‑approved complex generic portfolio and leveraging analytical services for contract manufacturing can drive revenue growth and market diversification.
Risk Factors
Regulatory delays, intense pricing competition, and the need for substantial capital to scale manufacturing pose significant challenges.
Competitive Landscape
Airis competes with large generic manufacturers such as Teva and Sandoz; its differentiation lies in its continuous‑quality platform and focus on high‑complexity formulations.